A Member of the University of Maryland Medical System   |   In Partnership with the University of Maryland School of Medicine

Share

Email PageEmail Print PagePrint

Home > Medical Reference > Encyclopedia (English)

Toggle: English / Spanish

Coriocarcinoma - Treatment

Nombres alternativos

Corioblastoma; Tumor trofoblástico; Corioepitelioma; Neoplasia trofoblástica gestacional

Tratamiento:

Después de un diagnóstico inicial, se hacen una historia clínica y un examen meticuloso para constatar que el cáncer no se haya diseminado a otros órganos. La quimioterapia es el tipo principal de tratamiento.

Rara vez se requiere una histerectomía y radioterapia.

Grupos de apoyo:

Para buscar información adicional, ver el artículo sobre recursos para el cáncer.

Expectativas (pronóstico):

La mayoría de las mujeres cuyo cáncer no se ha diseminado se puede curar y se preservará la función reproductiva.

La afección es difícil de curar si el cáncer se ha diseminado y se presenta una o más de las siguientes situaciones:

  • La enfermedad se ha diseminado al hígado o al cerebro
  • El nivel de la hormona del embarazo (GCH) es mayor a 40,000 mIU/mL en el momento del inicio del tratamiento
  • El cáncer retorna después de haber recibido quimioterapia anteriormente
  • Los síntomas o embarazo ocurrieron por más de cuatro meses antes de que empezara el tratamiento
  • El coriocarcinoma ocurrió después de un embarazo que dio como resultado el nacimiento de un niño

Muchas mujeres (alrededor del 70%) que inicialmente tienen un pronóstico desalentador experimentan remisión (un estado libre de la enfermedad).

Complicaciones:

Un coriocarcinoma puede reaparecer después del tratamiento, por lo general, al cabo de algunos meses, pero posiblemente hasta 3 años más tarde. También se pueden presentar complicaciones asociadas con la quimioterapia.

Situaciones que requieren asistencia médica:

Solicite una cita con el médico si se presentan síntomas dentro del año después de la aparición de una mola hidatiforme, de experimentar un aborto (incluyendo el aborto espontáneo) o de un embarazo a término.

  • Reviewed last on: 6/5/2010
  • Linda J. Vorvick, MD, Medical Director, MEDEX Northwest Division of Physician Assistant Studies, University of Washington, School of Medicine; Susan Storck, MD, FACOG, Chief, Eastside Department of Obstetrics and Gynecology, Group Health Cooperative of Puget Sound, Redmond, Washington; Clinical Teaching Faculty, Department of Obstetrics and Gynecology, University of Washington School of Medicine. Also reviewed by David Zieve, MD, MHA, Medical Director, A.D.A.M., Inc.

Referencias

Goldstein DP, Berkowitz RS. Gestational trophoblastic disease. In: Abeloff MD, Armitage JO, Niederhuber JE, Kastan MB, McKenna WG, eds. Abeloff’s Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier Churchill Livingstone; 2008:chap 94.

Kavanagh JJ, Gershenson DM. Gestational trophoblastic disease: hydatidiform mole, nonmetastatic and metastatic gestational trophoblastic tumor: diagnosis and management. In: Katz VL, Lentz GM, Lobo RA, Gershenson DM. Comprehensive Gynecology. 5th ed. Philadelphia, Pa: Mosby Elsevier; 2007:chap 35.

Soper J, Creasman JT. Gestational trophoblastic disease. In: Disaia PJ, Creasman WT, eds. Clinical Gynecologic Oncology. 7th ed. Philadelphia, Pa: Saunders Elsevier; 2007:chap 7.

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
adam.com
Adam QualityA.D.A.M., Inc. is accredited by URAC, also known as the American Accreditation HealthCare Commission (www.urac.org). URAC's accreditation program is an independent audit to verify that A.D.A.M. follows rigorous standards of quality and accountability. A.D.A.M. is among the first to achieve this important distinction for online health information and services. Learn more about A.D.A.M.'s editorial policy, editorial process and privacy policy. A.D.A.M. is also a founding member of Hi-Ethics and subscribes to the principles of the Health on the Net Foundation (www.hon.ch).

The information provided herein should not be used during any medical emergency or for the diagnosis or treatment of any medical condition. A licensed medical professional should be consulted for diagnosis and treatment of any and all medical conditions. Call 911 for all medical emergencies. Links to other sites are provided for information only -- they do not constitute endorsements of those other sites. © 1997- A.D.A.M., Inc. Any duplication or distribution of the information contained herein is strictly prohibited.
adam.com
Connect with UMMC
Facebook Twitter YouTube Blog iPhone

Please rate the quality of this article.

Do you find this article to be helpful / informative?
              
Poor                                       Excellent

Do you have any brief comments on this page: (up to 255 characters)

© 2011 University of Maryland Medical Center (UMMC). All rights reserved.
UMMC is a member of the University of Maryland Medical System,
22 S. Greene Street, Baltimore, MD 21201. TDD: 1-800-735-2258 or 1.866.408.6885